NetworkNewsWire Announces Publication on Biosynthesis for Medicinal-Grade Cannabinoids
New York, New York--(Newsfile Corp. - October 26, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.
The publication, titled, "How Biosynthesis is Revolutionizing Cannabinoid Pharmaceuticals," discusses cutting-edge technology used in the manufacture of cannabinoid medicines.
To view the full publication, visit: https://www.networknewswire.com/biosynthesis-revolutionizing-cannabinoid-pharmaceuticals/
"The issue is that plant-based processes (planting, growing, harvesting, extracting and purifying) result in active ingredients at varying concentration levels with inconsistent qualities, including impurities such as pesticides. Companies interested in this approach for their products need to establish vast and high-volume marijuana greenhouse growing operations. This is a huge expense, further compounded by the complex process to produce pharmaceutical grade cannabinoids that meet the GMP requirements for FDA approval. InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) has taken the inside track in the industry and has just completed the world's first-ever recorded study that successfully stitched together several key components in the drug development continuum for cannabinoid therapies.
"Following this success, InMed is scaling its manufacturing process and pursuing research into other medical conditions by leveraging its know-how in cannabinoid drug development. Because biosynthesized cannabinoids are identical to those found in nature, they have potentially fewer adverse events associated with varying drug structures and may confer better efficacy. Biosynthesis also avoids several of the drawbacks associated with growing marijuana, including elimination of pesticides that can be toxic to people and harmful to the environment."
About InMed
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed's proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the company.
For more information, visit www.InMedpharma.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.
NNW Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.